46 research outputs found
Comparing Nonparametric Bayesian Tree Priors for Clonal Reconstruction of Tumors
Statistical machine learning methods, especially nonparametric Bayesian
methods, have become increasingly popular to infer clonal population structure
of tumors. Here we describe the treeCRP, an extension of the Chinese restaurant
process (CRP), a popular construction used in nonparametric mixture models, to
infer the phylogeny and genotype of major subclonal lineages represented in the
population of cancer cells. We also propose new split-merge updates tailored to
the subclonal reconstruction problem that improve the mixing time of Markov
chains. In comparisons with the tree-structured stick breaking prior used in
PhyloSub, we demonstrate superior mixing and running time using the treeCRP
with our new split-merge procedures. We also show that given the same number of
samples, TSSB and treeCRP have similar ability to recover the subclonal
structure of a tumor.Comment: Preprint of an article submitted for consideration in the Pacific
Symposium on Biocomputing \c{opyright} 2015; World Scientific Publishing Co.,
Singapore, 2015; http://psb.stanford.edu
Inferring clonal evolution of tumors from single nucleotide somatic mutations
High-throughput sequencing allows the detection and quantification of
frequencies of somatic single nucleotide variants (SNV) in heterogeneous tumor
cell populations. In some cases, the evolutionary history and population
frequency of the subclonal lineages of tumor cells present in the sample can be
reconstructed from these SNV frequency measurements. However, automated methods
to do this reconstruction are not available and the conditions under which
reconstruction is possible have not been described.
We describe the conditions under which the evolutionary history can be
uniquely reconstructed from SNV frequencies from single or multiple samples
from the tumor population and we introduce a new statistical model, PhyloSub,
that infers the phylogeny and genotype of the major subclonal lineages
represented in the population of cancer cells. It uses a Bayesian nonparametric
prior over trees that groups SNVs into major subclonal lineages and
automatically estimates the number of lineages and their ancestry. We sample
from the joint posterior distribution over trees to identify evolutionary
histories and cell population frequencies that have the highest probability of
generating the observed SNV frequency data. When multiple phylogenies are
consistent with a given set of SNV frequencies, PhyloSub represents the
uncertainty in the tumor phylogeny using a partial order plot. Experiments on a
simulated dataset and two real datasets comprising tumor samples from acute
myeloid leukemia and chronic lymphocytic leukemia patients demonstrate that
PhyloSub can infer both linear (or chain) and branching lineages and its
inferences are in good agreement with ground truth, where it is available
Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction.
Tumor heterogeneity is a limiting factor in cancer treatment and in the discovery of biomarkers to personalize it. We describe a computational purification tool, ISOpure, to directly address the effects of variable normal tissue contamination in clinical tumor specimens. ISOpure uses a set of tumor expression profiles and a panel of healthy tissue expression profiles to generate a purified cancer profile for each tumor sample and an estimate of the proportion of RNA originating from cancerous cells. Applying ISOpure before identifying gene signatures leads to significant improvements in the prediction of prognosis and other clinical variables in lung and prostate cancer
ISOpureR: an R implementation of a computational purification algorithm of mixed tumour profiles
Background
Tumour samples containing distinct sub-populations of cancer and normal cells present challenges in the development of reproducible biomarkers, as these biomarkers are based on bulk signals from mixed tumour profiles. ISOpure is the only mRNA computational purification method to date that does not require a paired tumour-normal sample, provides a personalized cancer profile for each patient, and has been tested on clinical data. Replacing mixed tumour profiles with ISOpure-preprocessed cancer profiles led to better prognostic gene signatures for lung and prostate cancer.
Results
To simplify the integration of ISOpure into standard R-based bioinformatics analysis pipelines, the algorithm has been implemented as an R package. The ISOpureR package performs analogously to the original code in estimating the fraction of cancer cells and the patient cancer mRNA abundance profile from tumour samples in four cancer datasets.
Conclusions
The ISOpureR package estimates the fraction of cancer cells and personalized patient cancer mRNA abundance profile from a mixed tumour profile. This open-source R implementation enables integration into existing computational pipelines, as well as easy testing, modification and extension of the model.Prostate Cancer CanadaMovember Foundation (Grant RS2014-01
Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig
The type and genomic context of cancer mutations depend on their causes. These causes have been characterized using signatures that represent mutation types that co-occur in the same tumours. However, it remains unclear how mutation processes change during cancer evolution due to the lack of reliable methods to reconstruct evolutionary trajectories of mutational signature activity. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole-genome sequencing data from 2658 cancers across 38 tumour types, we present TrackSig, a new method that reconstructs these trajectories using optimal, joint segmentation and deconvolution of mutation type and allele frequencies from a single tumour sample. In simulations, we find TrackSig has a 3-5% activity reconstruction error, and 12% false detection rate. It outperforms an aggressive baseline in situations with branching evolution, CNA gain, and neutral mutations. Applied to data from 2658 tumours and 38 cancer types, TrackSig permits pan-cancer insight into evolutionary changes in mutational processes
ISOpureR: an R implementation of a computational purification algorithm of mixed tumour profiles
PhyloWGS: Reconstructing subclonal composition and evolution from whole-genome sequencing of tumors
The evolutionary history of 2,658 cancers.
Cancer develops through a process of somatic evolution1,2. Sequencing data from a single biopsy represent a snapshot of this process that can reveal the timing of specific genomic aberrations and the changing influence of mutational processes3. Here, by whole-genome sequencing analysis of 2,658 cancers as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA)4, we reconstruct the life history and evolution of mutational processes and driver mutation sequences of 38 types of cancer. Early oncogenesis is characterized by mutations in a constrained set of driver genes, and specific copy number gains, such as trisomy 7 in glioblastoma and isochromosome 17q in medulloblastoma. The mutational spectrum changes significantly throughout tumour evolution in 40% of samples. A nearly fourfold diversification of driver genes and increased genomic instability are features of later stages. Copy number alterations often occur in mitotic crises, and lead to simultaneous gains of chromosomal segments. Timing analyses suggest that driver mutations often precede diagnosis by many years, if not decades. Together, these results determine the evolutionary trajectories of cancer, and highlight opportunities for early cancer detection
Recommended from our members
Inferring structural variant cancer cell fraction
Abstract: We present SVclone, a computational method for inferring the cancer cell fraction of structural variant (SV) breakpoints from whole-genome sequencing data. SVclone accurately determines the variant allele frequencies of both SV breakends, then simultaneously estimates the cancer cell fraction and SV copy number. We assess performance using in silico mixtures of real samples, at known proportions, created from two clonal metastases from the same patient. We find that SVclone’s performance is comparable to single-nucleotide variant-based methods, despite having an order of magnitude fewer data points. As part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium, which aggregated whole-genome sequencing data from 2658 cancers across 38 tumour types, we use SVclone to reveal a subset of liver, ovarian and pancreatic cancers with subclonally enriched copy-number neutral rearrangements that show decreased overall survival. SVclone enables improved characterisation of SV intra-tumour heterogeneity